PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro cell culture and animal experiment without human subjects
PubMed 18061177 · doi:10.1053/j.gastro.2007.10.026
What was done
Researchers investigated the mechanism and anti-inflammatory activity of the tripeptide KPV (Lys-Pro-Val). In vitro, human intestinal epithelial cell lines (Caco2-BBE, HT29-Cl.19A) and human T cells (Jurkat) were stimulated with pro-inflammatory cytokines with or without KPV, evaluating NF-kappaB and MAP kinase signaling, cytokine secretion, and radiolabeled uptake kinetics to assess PepT1 transport. In vivo, mice with DSS- and TNBS-induced colitis received KPV in drinking water, and intestinal inflammation was assessed histologically and via cytokine mRNA expression.
What was found
The abstract reports no exact numbers, percentages, or effect sizes. It qualitatively reports that nanomolar concentrations of KPV inhibited NF-kappaB and MAP kinase signaling pathways, reduced pro-inflammatory cytokine secretion, and entered cells via the PepT1 transporter. In both DSS- and TNBS-induced mouse colitis models, oral KPV reduced the incidence of colitis and decreased pro-inflammatory cytokine expression.
Why it matters
The study identifies PepT1 as the uptake transporter for KPV in intestinal and immune cells, suggesting a mechanistic target for peptide-based anti-inflammatory therapies in inflammatory bowel disease.
Limits
This is entirely preclinical research conducted in transformed human cell lines and chemically induced mouse models of colitis, which do not fully replicate human inflammatory bowel disease. The abstract provides no sample sizes (n for animals or experimental replicates), quantitative values, confidence intervals, or toxicity and safety data.
Cited by
- supports The peptide KPV reduces interleukin-6 and TNF-alpha in the gut, which are inflammatory cytokines driving gut inflammation and permeability.